Axel Hohenstein | CSO
Bioassay - A Reaction Biology Company
Axel joined Bioassay in 2007 as Scientists after covering the role of Laboratory Head of Department of Cell and Molecular Biology at Biotest AG. Upon joining Bioassay Axel quickly rose through the ranks and became Managing Director in 2010. In his new role he was involved in the acquisition of Peptide Specialty Laboratories GmbH by Bioassay which he successfully completed in 2017.
Axel earned his magna cum laude Doctorate from the University of Heidelberg, probing angiogenic factors in chronic subdural hematoma.
Immediately after graduating in Biotechnology from the University of Mannheim, Axel worked as Bio-Engineer at BRAIN AG where he perfected his assay development skills.
Axel’s extensive experience includes a profound understanding of GMP, GLP, and FDA approval processes, underscoring his commitment to maintaining the highest standards of quality and integrity. His collaborative approach and aptitude for fostering partnerships have enabled him to cultivate a global network of industry connections.
Axel is currently Managing Director and CSO at Bioassay.
Appearances:
Festival of Biologics Day 2 @ 13:00
Advancing Peptide Therapeutics: Cell-Based Potency Assays for GLP-1, GLP-2, and GIP Receptor Agonists
Peptide-based drugs represent a cornerstone of modern therapeutics, particularly in the treatment of metabolic disorders. In the evolving landscape of obesity research, GLP-1, GLP-2, and GIP receptors have emerged as key targets for next-generation therapies. Reaction Biology supports this innovation by offering custom research-grade peptide synthesis and robust cell-based potency assays tailored to these receptor systems.
Our assay platform utilizes an indirect cAMP readout to quantify receptor activation, enabling precise IC₅₀ determination for each receptor independently. This approach supports both early-stage drug development and batch release testing. We demonstrate the platform’s capabilities through in-house synthesis of Semaglutide, development of a GLP-1 assay using Saxenda as a model agonist, and comparative analysis of marketed reference compounds including Liraglutide, Tirzepatide, and Teduglutide.
By enabling receptor-specific potency profiling and supporting single- or dual-receptor targeting strategies, our assay system provides a powerful tool for advancing peptide drug discovery. Importantly, these assays can also be performed under GMP conditions for batch release testing.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events